一年一度的肿瘤领域盛会——2025年欧洲肿瘤内科学会年会（ESMO 2025）将于10月17日至21日在德国柏林隆重举行，届时将揭示众多前沿临床科研成果，并吸引全球知名专家教授进行研讨，共同促进临床肿瘤学的发展与进步。
目前，官网披露了本次大会的入选摘要标题，在胃
1 摘要号：2097P
研究名称（英文）：A Randomized, Multicenter, Phase III trial to Compare Neoadjuvant Chemoradiotherapy versus Chemotherapy in Patients with Locally Advanced Gastric Adenocarcinoma (Neo-CRAG).
讲者：Wei Wang | 中国广州
2 摘要号：2098P
研究名称（英文）：Cadonilimab (Cado) plus chemotherapy (chemo) versus chemotherapy as first-line (1L) treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: final results of the Phase Ⅲ COMPASSION-15 trial
讲者：Feng Xu | 中国上海
3 摘要号：2101P
研究名称（英文）：Dose Escalation in Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Long-Term Results and Exploratory Analyses from a Randomized Phase III Trial
讲者：Yujin Xu | 中国杭州
4 摘要号：2104P
研究名称（英文）：Final Analysis and Biomarker Evaluation of JUPITER-06: A Phase 3 Trial of Toripalimab Plus Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
讲者：王峰 | 中山大学肿瘤防治中心
5 摘要号：2105P
研究名称（英文）：Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA) who received prior anti-HER2 treatment (Tx) other than / in addition to trastuzumab in DESTINY-Gastric06 (DG-06)
讲者：彭智 | 北京大学肿瘤医院
6 摘要号：2108P
研究名称（英文）：Health-related quality of life with first-line SHR-1701 versus placebo plus chemotherapy for HER2-negative gastric or gastroesophageal junction adenocarcinoma: results from a randomized phase 3 trial
讲者：彭智 | 北京大学肿瘤医院
7 摘要号：2109P
研究名称（英文）：First-line tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced/metastatic esophageal squamous cell carcinoma (ESCC): A post-hoc analysis of different investigator-choice CT and tumor PD-L1 expression level subgroups in RATIONALE-306
讲者：Jhe-Cyuan Guo | 中国台北
8 摘要号：2113P
研究名称（英文）：Phase 1/2 study of claudin 18.2 ADC ATG-022 in Patients with advanced gastric/gastroesophageal junction cancer (CLINCH)
讲者：Jinfeng Ma | 中国太原
9 摘要号：2116P
研究名称（英文）：FS-1502 combined with serplulimab in patients with HER2 expression, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJ): An open-label, multicenter, phase II study
讲者：龚继芳 | 北京大学肿瘤医院
10 摘要号：2118P
研究名称（英文）：Perioperative Sintilimab Plus Oxaliplatin and S-1 (SOX) versus SOX Alone in Resectable Locally Advanced Gastric Cancer/Gastroesophageal Junction Cancer (GC/GEJC): A Multicenter Randomized Phase II Study (PERSIST)
讲者：丁学伟 | 天津医科大学肿瘤医院
11 摘要号：2119P
研究名称（英文）：Perioperative Study of BTLA Combined with PD-1 and Chemotherapy as Bispecific Immunosuppressants for Resectable Thoracic Esophageal Squamous Cell Carcinoma (BT-NICE trial): A Prospective, Single Group, Phase II Study
讲者：丁成智 | 河南省人民医院
12 摘要号：2120P
研究名称（英文）：Long-Term Survival and Association of Neoadjuvant Chemotherapy with or without Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma
讲者：Lin Lu | 中国南京
13 摘要号：2121P
研究名称（英文）：Sintilimab plus Bevacizumab Biosimilar IBI305 and Chemotherapy as First-line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (SBAGA): a Single-arm, Phase Ib/II Study
讲者：Mo Cheng | 中国成都
14 摘要号：2123P
研究名称（英文）：Sintilimab combined with short-course intensified chemotherapy regimen Nab-POF in the treatment of metastatic gastric cancer (FDZL-GC002) : a single-arm, phase 2 trial
讲者：郭伟剑 | 复旦大学附属肿瘤医院
15 摘要号：2124P
研究名称（英文）：Sintilimab plus Chemoradiotherapy as First-line Treatment for Stage IV ESCC with Non-Regional Node Metastases only: A Phase II Clinical Trial
讲者：王琳琳 | 山东第一医科大学附属肿瘤医院
16 摘要号：2125P
研究名称（英文）：A phase Ⅱ study of simmitinib in combination with liposomal irinotecan for second-line treatment of advanced esophageal squamous cell carcinoma
讲者：Yue Ma | 中国哈尔滨
17 摘要号：2127P
研究名称（英文）：Neoadjuvant Low Dose Radiotherapy Combined with Tislelizumab and Chemotherapy in Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (GAS-Jiangsu 01): A Single-arm Phase II Trial
讲者：Gang Li | 中国南京
18 摘要号：2128P
研究名称（英文）：Total neoadjuvant chemotherapy plus PD-1 antibody in locally advanced gastric or gastro-esophageal junction adenocarcinoma: A proof-of-concept, phase 2 trial
讲者：聂润聪 | 中山大学肿瘤防治中心
19 摘要号：2129P
研究名称（英文）：Transarterial infusion chemotherapy and embolization (TAICE) as a pre-operative therapy for patients with locally advanced gastric cancer (LAGC): A phase II trial (TAICE-02)
讲者：Zheng Liu | 中国上海
20 摘要号：2130P
研究名称（英文）：HuA21 combined with trastuzumab and chemotherapy in HER2-positive advanced gastric/GEJ adenocarcinoma: Phase Ib/II dose-escalation and expansion study(CTR20240640)
讲者：刘天舒 | 复旦大学附属中山医院
21 摘要号：2131P
研究名称（英文）：Adebrelimab Plus Apatinib in Advanced Esophageal Squamous Cell Carcinoma Following Immune Checkpoint Inhibitors: Preliminary Results from Cohort 3 of CAP 02 Study
讲者：Jun Zhao | 中国长治
22 摘要号：2132P
研究名称（英文）：A promising readout from the phase I trial of IMC002, VHH-based anti-Claudin18.2 CAR-T cells for gastrointestinal cancers.
讲者：Chao Li | 中国北京
23 摘要号：2133P
研究名称（英文）：Exploratory biomarker analysis of the phase 3 RATIONALE 305 trial: First-line (1L) tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT for advanced gastric cancer/gastro-oesophageal junction adenocarcinoma (GC/GEJC)
讲者：邱妙珍 | 中山大学肿瘤防治中心
24 摘要号：2135P
研究名称（英文）：FS-1502 in patients with HER2 expression, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJ): An open-label, multicenter, phase II study
讲者：Yu Zheng | 中国杭州
25 摘要号：2138P
研究名称（英文）：First-in-human study of BA1301, a novel CLDN18.2-targeting antibody-drug conjugate in advanced solid tumors
讲者：张艳桥 | 哈尔滨医科大学附属肿瘤医院
26 摘要号：2139P
研究名称（英文）：SKB315, a novel Claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors including gastric/ gastroesophageal junction cancer (GC/GEJC): a phase 1 study
讲者：邓婷 | 天津医科大学肿瘤医院
27 摘要号：2143P
研究名称（英文）：Impact of First-line Chemoimmunotherapy with or without Radiotherapy on the Prognosis of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Multicenter, Real-World, Retrospective Cohort Study from China
讲者：Xinyi Liu | 中国石家庄
28 摘要号：2145P
研究名称（英文）：Neoadjuvant camrelizumab plus chemotherapy versus chemotherapy alone for resectable esophageal squamous cell carcinoma: Primary efficacy/safety results and exploratory single-cell RNA sequencing correlates from a multicenter, prospective, randomized controlled study.
讲者：张仁泉 | 安徽医科大学第一附属医院
29 摘要号：2146P
研究名称（英文）：First-in-human clinical performance of novel 99mTc-PHG102 radiotracer targeting Claudin18.2 in esophagogastric cancer
讲者：Xin Xie | 中国西安
30 摘要号：2148P
研究名称（英文）：Handgrip Strength and Albumin-Globulin Ratio Predict Survival in Esophageal Cancer: A Multicenter Cohort Study
讲者：Xiangting Dai | 中国北京
31 摘要号：2153P
研究名称（英文）：Uncovering HRD Biomarkers Beyond BRCA in Chinese Esophageal Squamous Cell Carcinoma
讲者：Jingping Yu | 中国常州
32 摘要号：2154P
研究名称（英文）：Prognostic Value of cfDNA Methylation in Predicting the Efficacy of Neoadjuvant Chemoradiotherapy Combined with anti-PD-1 in Locally Advanced Esophageal Squamous Cell Cancer
讲者：陈宝清 | 中山大学肿瘤防治中心
33 摘要号：2159P
研究名称（英文）：Fruquintinib plus sintilimab and SOX as conversion therapy for initially unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated surgical and survival results from the single-arm, phase 2 clinical trial
讲者：马飞 | 河南省肿瘤医院
34 摘要号：2161P
研究名称（英文）：Tislelizumab Combined with POFI (Irinotecan, Paclitaxel, Oxaliplatin, and 5-FU/Levoleucovorin) as First-Line Treatment for Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (AGC): Preliminary Results from a Single-Arm, Open-Label Phase II Trial (SYLT-023)
讲者：林榕波 | 河南省肿瘤医院
35 摘要号：2162P
研究名称（英文）：Efficacy and Safety of Neoadjuvant Thymalfasin, Serplulimab, and SOX in cStage III G/EGJ Adenocarcinoma (GATES): a single-center, single-arm, phase 2 trial
讲者：Hongda Liu | 中国南京
36 摘要号：2163P
研究名称（英文）：Safety and efficacy of simmitinib in patients(pts) with advanced solid tumors, a phase 1 study
讲者：杨声 | 首都医科大学附属北京胸科医院
37 摘要号：2165P
研究名称（英文）：Neoadjuvant adebrelimab plus chemotherapy for locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: A single-arm, open-label, phase II trial
讲者：Jiaxing He | 中国西安
38 摘要号：2167P
研究名称（英文）：Comparative Immune-Pathological Responses to Neoadjuvant Chemoimmunotherapy and Chemotherapy in Esophageal Squamous Cell Carcinoma and Development of a Prognostic Model
讲者：Jingwen Li | 中国南京
39 摘要号：2169P
研究名称（英文）：A Multi-Omics Predictive Model for Radiation-Induced Cardiac Toxicity in Esophageal Cancer Patients treated with Definitive Chemoradiotherapy
讲者：Tianlu Tang | 中国上海
40 摘要号：2175P
研究名称（英文）：Risk of hepatitis B virus reactivation (HBVr) in patients (pts) with past or resolved HBV or inactive chronic HBV infection treated with trastuzumab deruxtecan (T-DXd) in DESTINY-Gastric06 (DG-06)
讲者：
备注：排名不分先后
如有遗漏或任何问题，请给我们留言~
(本网站所有内容，凡注明来源为“医脉通”，版权均归医脉通所有，未经授权，任何媒体、网站或个人不得转载，否则将追究法律责任，授权转载时须注明“来源：医脉通”。本网注明来源为其他媒体的内容为转载，转载仅作观点分享，版权归原作者所有，如有侵犯版权，请及时联系我们。)
